Sysmex (OTCMKTS:SSMXY) Releases FY 2024 Earnings Guidance

Sysmex (OTCMKTS:SSMXY) issued an update on its FY 2024 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 0.580-0.580 for the period. The company issued revenue guidance of $3.3 billion-$3.3 billion.

Sysmex Trading Down 0.3 %

Shares of OTCMKTS:SSMXY traded down $0.06 during trading on Thursday, reaching $18.22. The stock had a trading volume of 75,584 shares, compared to its average volume of 84,987. Sysmex has a 52 week low of $14.38 and a 52 week high of $28.58. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.42 and a current ratio of 3.19. The firm’s fifty day moving average is $18.86 and its 200 day moving average is $19.02. The stock has a market cap of $11.47 billion, a price-to-earnings ratio of 36.91 and a beta of 0.90.

Sysmex (OTCMKTS:SSMXY) last announced its earnings results on Wednesday, February 12th. The company reported $0.17 EPS for the quarter. As a group, equities analysts forecast that Sysmex will post 0.57 EPS for the current fiscal year.

Sysmex Company Profile

Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. It offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs. The company also provides automated urine particle analyzers; automated blood coagulation analyzers; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for infectious disease and tumor markers; and flow cytometers to perform analysis in diagnosing leukemia, malignant lymphoma, and HIV/AIDS.